BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NNNN), a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international ...

Anbio Biotechnology reported strong 2025 results with sales of $8.65M. The company is diversifying away from COVID products.

NNNN continues pivoting toward better profitability metrics. They’ve prioritized high-margin orders over sales volume. In practice, this has improved near-term operating metrics, but their topline has ...

Explore Anbio Biotechnology analyst ratings and price targets (NASDAQ:NNNN) on Benzinga. Stay updated on expert opinions and forecasts for NNNN stock. There is no next analyst rating for Anbio ...

View Anbio Biotechnology Class A NNNN stock quote prices, financial information, real-time forecasts, and company news from CNN.

BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international ...

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 ...

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is ...

Anbio Biotechnology Class A ( (NNNN)) has issued an announcement. Anbio Biotechnology has convened a meeting of Class A shareholders and an extraordinary general meeting for May 15, 2026, in Frankfurt ...

Anbio Biotechnology (NASDAQ:NNNN) is one of the 13 Best German Stocks to Invest in Now. The company is engaged in the development of medical technology and the provision of in vitro diagnostics ...

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.